Saad Usmani to Infusions, Intravenous
This is a "connection" page, showing publications Saad Usmani has written about Infusions, Intravenous.
Connection Strength
0.525
-
Hamadeh IS, Moore DC, Martin A, Karabinos A, Hill H, Ndiaye A, Robinson JD, Paul BA, Atrash S, Bhutani M, Voorhees PM, Usmani SZ. Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice. Clin Lymphoma Myeloma Leuk. 2021 07; 21(7):470-475.
Score: 0.172
-
Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Yang H, Klippel Z, Zahlten-Kumeli A, Usmani SZ. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020 07 18; 396(10245):186-197.
Score: 0.165
-
Arnall JR, Moore DC, Hill HL, Griffin S, Mueller MK, Lavery LA, Voorhees PM, Usmani SZ. Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses. Leuk Lymphoma. 2019 09; 60(9):2295-2298.
Score: 0.150
-
Chari A, Lonial S, Mark TM, Krishnan AY, Stockerl-Goldstein KE, Usmani SZ, Londhe A, Etheredge D, Fleming S, Liu B, Ukropec J, Lin TS, Jagannath S, Nooka AK. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. Cancer. 2018 11 15; 124(22):4342-4349.
Score: 0.037